JPL Wealth Management
ALNY icon

JPL Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

JPL Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.9K Sell
40
-8
-17% -$2.04K ﹤0.01% 491
2026
Q2 		$14.5K Hold
48
– – ﹤0.01% 502
2026
Q1 		$15.9K Buy
+48
New +$16.3K ﹤0.01% 437
2025
Q4 		– Sell
-46
Closed -$21K – 156
2025
Q3 		$21K Buy
+46
New +$18.7K 0.01% 392

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JPL Wealth Management's ALNY Position: Q3 2026 in Review

JPL Wealth Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 17% in Q3 2026, selling an estimated $2.04K and leaving 40 shares worth $9.9K. The position accounts for ﹤0.01% of the portfolio, ranked #491.

JPL Wealth Management first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $21K in Q3 2025. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • JPL Wealth Management held 40 shares of Alnylam Pharmaceuticals worth $9.9K as of Q3 2026.
  • JPL Wealth Management sold 8 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $2.04K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of JPL Wealth Management's portfolio in Q3 2026, its #491 holding.
  • JPL Wealth Management first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • JPL Wealth Management's Alnylam Pharmaceuticals position peaked at $21K in Q3 2025.
  • 591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on JPL Wealth Management's 13F filing for Q3 2026, filed 13 Nov 2026.